Inflammatory Bowel Diseases

Skip Navigation LinksHome > July 2013 - Volume 19 - Issue 8 > Epstein–Barr Virus in Inflammatory Bowel Disease—Correlation...
Inflammatory Bowel Diseases:
doi: 10.1097/MIB.0b013e318281f31c
Original Clinical Articles

Epstein–Barr Virus in Inflammatory Bowel Disease—Correlation with Different Therapeutic Regimens

Magro, Fernando MD, PhD*,†,‡; Santos-Antunes, João MD*,§; Albuquerque, Andreia MD*; Vilas-Boas, Filipe MD*; Macedo, Gonçalo N. BSc; Nazareth, Nair BSc; Lopes, Susana MD*; Sobrinho-Simões, Joana MD; Teixeira, Sérgio BSc; Dias, Cláudia Camila BSc**; Cabral, José BSc; Sarmento, Amélia PhD‡,‖; Macedo, Guilherme MD, PhD*

Collapse Box


Background: Inflammatory bowel disease (IBD) is associated with a higher prevalence of opportunistic infections. Epstein–Barr virus (EBV) is a ubiquitous virus related to several malignancies, namely lymphoma; its prevalence in patients with IBD and its relation with different therapeutic regimens are not well studied.

Methods: Patients followed in our IBD outpatient clinic were consecutively enrolled for participation in a prospective study, and healthy volunteers were recruited as controls. EBV DNA was measured at least 1 time in each patient.

Results: Three hundred and seventy-nine individuals were enrolled in the study (93 treated with 5-aminosalicylates, 91 with azathioprine, 70 with infliximab, 43 with combined treatment with infliximab and azathioprine, and 82 controls). More than 90% of the patients had previous EBV exposure. EBV DNA was found in 132 samples (35%); its prevalence was significantly higher in every group of patients with IBD, comparing to controls. Among patients with IBD, infliximab with or without azathioprine was related to higher prevalence of EBV comparing to azathioprine alone or 5-aminosalicylates (P < 0.05). Age above 60 years was related to EBV DNA positivity with a specificity of 92%. Concerning treated groups, ulcerative colitis was the only risk factor identified for high levels of EBV DNA (>1000 and 2500 copies per milliliter). No relationship was found between EBV and C-reactive protein.

Conclusions: IBD is a risk factor for the presence of EBV DNA in blood, particularly in older patients and in those taking infliximab. C-reactive protein was not related to EBV DNA prevalence.

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.